Cargando…

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Roussou, Maria, Eleutherakis-Papaiakovou, Evangelos, Spiliopoulou, Vassiliki, Kastritis, Efstathios, Terpos, Evangelos, Dimopoulos, Meletios-Athanasios, Gavriatopoulou, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380484/ https://www.ncbi.nlm.nih.gov/pubmed/37511588 http://dx.doi.org/10.3390/ijms241411829

Ejemplares similares

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
por: Terpos, Evangelos, et al.
Publicado: (2023)

P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2022)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2023)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
por: Theodorakakou, Foteini, et al.
Publicado: (2023)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
por: Malandrakis, Panagiotis, et al.
Publicado: (2023)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
por: Kastritis, Efstathios, et al.
Publicado: (2023)

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
por: Terpos, Evangelos, et al.
Publicado: (2021)

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Terpos, Evangelos, et al.
Publicado: (2022)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
por: Terpos, Evangelos, et al.
Publicado: (2020)

Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy: A case report
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients
por: Kanellias, Nikolaos, et al.
Publicado: (2022)

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
por: Spiliopoulou, V., et al.
Publicado: (2023)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
por: Papatsirou, Maria, et al.
Publicado: (2023)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2018)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Emerging treatment strategies for COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
por: Kastritis, Efstathios, et al.
Publicado: (2017)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients
por: Fotiou, Despina, et al.
Publicado: (2020)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2018)

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA
por: Malandrakis, P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cmh51urio9koam2v8upiro8usp